AMW GmbH, a Warngau, a near Munich, Germany-based medical technology company, raised €6m in funding.
Backers included the Bavarian growth fund Wachstumsfonds Bayern, which is managed by Bayern Kapital, and SHS Gesellschaft für Beteiligungsmanagement among others.
The company intends to use the funds to promote the development of new products and expand production capacities.
Established in 2008, AMW has developed systems to administer precisely dosed drugs to patients via transdermal patches or subcutaneous implants. The company, which employs 64 people, provides treatment solutions in the areas of oncology, neurology, psychiatry, pain therapy, contraception and diabetes.